Mara Epstein to Multiple Myeloma
This is a "connection" page, showing publications Mara Epstein has written about Multiple Myeloma.
Connection Strength
4.408
-
Epstein MM, Zhou Y, Castaneda-Avila MA, Cohen HJ. Multimorbidity in patients with monoclonal gammopathy of undetermined significance. Int J Cancer. 2023 06 15; 152(12):2485-2492.
Score: 0.590
-
Casta?eda-Avila MA, Mazor KM, Lapane KL, Epstein MM. Patient and provider-level drivers of healthcare utilization related to a diagnosis of a precancerous condition: monoclonal gammopathy of undetermined significance (MGUS). Cancer Causes Control. 2023 May; 34(5):449-457.
Score: 0.590
-
Casta?eda-Avila MA, Lapane KL, Person SD, Zhou Y, Gurwitz J, Mazor KM, Epstein MM. Multi-trajectory models of serum biomarkers among patients with monoclonal gammopathy of undetermined significance. Hematol Oncol. 2022 Aug; 40(3):409-416.
Score: 0.554
-
Casta?eda-Avila MA, Lapane KL, Person SD, Jesdale BM, Zhou Y, Mazor KM, Epstein MM. Differences in Hospital, Emergency Room and Outpatient Visits Among Adults With and Without Monoclonal Gammopathy of Undetermined Significance. Cancer Control. 2022 Jan-Dec; 29:10732748221126936.
Score: 0.545
-
Casta?eda-Avila MA, Jesdale BM, Beccia A, Bey GS, Epstein MM. Differences in survival among multiple myeloma patients in the United States SEER population by neighborhood socioeconomic status and race/ethnicity. Cancer Causes Control. 2021 Sep; 32(9):1021-1028.
Score: 0.523
-
Epstein MM, Saphirak C, Zhou Y, LeBlanc C, Rosmarin AG, Ash A, Singh S, Fisher K, Birmann BM, Gurwitz JH. Identifying monoclonal gammopathy of undetermined significance in electronic health data. Pharmacoepidemiol Drug Saf. 2020 01; 29(1):69-76.
Score: 0.470
-
Casta?eda-Avila MA, Ortiz-Ortiz KJ, Torres-Cintr?n CR, Birmann BM, Epstein MM. Trends in cause of death among patients with multiple myeloma in Puerto Rico and the United States SEER population, 1987-2013. Int J Cancer. 2020 01 01; 146(1):35-43.
Score: 0.450
-
Epstein MM, Divine G, Chao CR, Wells KE, Feigelson HS, Scholes D, Roblin D, Ulcickas Yood M, Engel LS, Taylor A, Fortuny J, Habel LA, Johnson CC. Statin use and risk of multiple myeloma: An analysis from the cancer research network. Int J Cancer. 2017 08 01; 141(3):480-487.
Score: 0.395
-
Casta?eda-Avila MA, Su?rez-Ramos T, Torres-Cintr?n CR, Epstein MM, Gierbolini-Berm?dez A, Tortolero-Luna G, Ortiz-Ortiz KJ. Multiple myeloma incidence, mortality, and survival differences at the intersection of sex, age, and race/ethnicity: A comparison between Puerto Rico and the United States SEER population. Cancer Epidemiol. 2024 Apr; 89:102537.
Score: 0.157
-
Fillmore NR, DuMontier C, Yildirim C, La J, Epstein MM, Cheng D, Cirstea D, Yellapragada S, Abel GA, Gaziano JM, Do N, Brophy M, Kim DH, Munshi NC, Driver JA. Defining Multimorbidity and Its Impact in Older United States Veterans Newly Treated for Multiple Myeloma. J Natl Cancer Inst. 2021 08 02; 113(8):1084-1093.
Score: 0.132